



AVICANNA™

A Global Leader in Innovative Biopharmaceutical Advancements Using Cannabinoids

Avicanna.com

TSX: AVCN

OTCQX: AVCNF

FSE: ONN

April 2020

Forward-Looking Statement



This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.'s ("Avicanna") business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about anticipated dates for revenue recognition; anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; intended quality standards of our joint venture with Sigma Analytics; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely impact our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol ("CBD"); security threats, including a loss/ theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; our dependence on key personnel and additional risk factors included under the heading "Risk Factors" in Avicanna's long-form prospectus dated July 8, 2019. Avicanna is an early stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna's expectations include, consumer sentiment towards Avicanna's products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counter-parties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, and unexpected delays in the commercialization of products. Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

Financial & Third Party Information

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Avicanna cannot guarantee the accuracy of such information, however, and has not independently verified the assumptions on which such information is based. Avicanna does not assume any responsibility for the accuracy or completeness of such information.

Avicanna is leading the development of advanced and natural cannabinoid solutions through an evidence-based, biopharmaceutical approach which is offered across several product platforms including dermacosmetics, medical and pharmaceutical applications.

Avicanna ensures the safety and quality standards of its products through it's global vertically integrated business model, including organic and sustainable cultivation, extraction, manufacturing, commercialization, R&D, and clinical infrastructure.



AVICANNA

Corporate Overview

Delivering Cannabinoid Products Through Science



- A biopharmaceutical company developing, manufacturing and commercializing various cannabinoid-based products for the global market place including:



Consumer Retail Products

Commerical



Medical Products

Commerical



Active Pharmaceutical Ingredients

Commerical



Pharmaceuticals

In Clinical Development



- Multi-national operations of 20+ scientists and clinicians in four licensed cannabinoid laboratories developing proprietary formulations.



- USDA organic certified cultivation practices for our hemp cultivars through our Colombian subsidiary: Santa Marta Golden Hemp S.A.S..



- Current annual cultivation capacity of approximately 20,000 kilograms through 410,000 square feet of cultivation space.



- Ranked highest amongst global cannabis companies participating in the SAM Corporate Sustainability Assessment (CSA) issued by S&P Global.

Global Cannabis Industry Segments

A Strictly Medical and Evidence-Based Approach



Medical Cannabis: Non-registered plant-derived cannabis products supported by health care practitioners. Limited pharmacology, regulatory and stability requirements through cannabis specific regulations.



Pharmaceutical cannabis: Indication specific drugs that have been through full clinical trials and registration with the relevant drug authorities. Examples of products include Sativex, Epidiolex, Cesamet, Marinol and Syndros.




Recreational cannabis: Ordinarily has a higher concentration of THC, the psychoactive properties of the cannabis plant. People tend to smoke or ingest cannabis or use oils and vaporized products.



CBD infused products: Consumer goods, cosmetics, capsules and oils. Although these products may be used for wellness purposes such as to aid sleep, or for pain or anxiety management, they do not require a prescription.

Cannabis Industry Current Outlook: Risks and Concerns



- **Inefficient cultivation practices leading to uncompetitive practices**
- **Environmentally unsustainable cultivation practices**



- **Insufficient research and clinical development of cannabinoid-based medicines**
- **Limited product offerings including unsophisticated and non-specialized medical offerings**
- **Lack of separation between medical and recreational product offerings and companies**



- **Public health concerns around quality, safety and stability**
- **Lack of standardization, traceability, and trackability of finished products**
- **Lack of education and warning of risks associated to THC use**

Global Leader in Advanced Cannabinoid Research and Pharmaceutical Development



Experienced and Multi-national Team Of 20+ Scientists And Clinicians

Four Cannabinoid Licensed Research Laboratories in Toronto, Bogotá, and Santa Marta.



R&D Headquarters at the MaRS Discovery District

Cannabis Research Licence issued by Health Canada to Avicanna at JLABS @ Toronto located in the MaRS Discovery District, the world's largest urban innovation hub, where Avicanna's scientists conduct research in collaboration with world-class researchers, academic, and clinical institutions.



Exclusive Collaboration Agreement with Dr. Christine Allen's Research Group ("CARG") at the University of Toronto

Cannabis Research Licence issued by Health Canada to Dr. Christine Allen's laboratory at the Leslie Dan Faculty of Pharmacy at the University of Toronto

Focused on Avicanna's pharmaceutical pipeline, including development and characterization through *in vitro* and *in vivo* analysis.



World-Class and Sustainable Value Chain: Cultivation, Production, and Manufacturing



2 Fully Licensed Cultivation Subsidiaries

Santa Marta Golden Hemp S.A.S. and Sativa Nativa S.A.S., both majority owned and managed subsidiaries of Avicanna

Organic and sustainable cultivation of cannabis in Santa Marta Colombia (SMGH is USDA Certified to cultivate organic hemp)

Low cost, industrial-scale cultivation infrastructure with an approximate annual capacity of 20,000 kilograms through 410,000 square feet of cultivation space

Utilizing optimal climate conditions allowing for consistent and reproducible crops



Extraction, Production, and Purification

In-house extraction and isolation infrastructure of cannabinoids in compliance with GMP and pharmaceutical standards

Joint venture with Sigma Analytics to build the first GMP quality control cannabinoid analytical laboratory and independent testing service in South America to meet Health Canada, European Pharmacopeia, US Pharmacopeia standards (“USP”)



Manufacturing

Exclusive contract manufacturing agreement with Altea Farmaceutica S.A.

Pharmaceutical, phytotherapeutic, and derma-cosmetic products manufactured in accordance with GMP certification by Health Canada, ANVISA (Brazil) and INVIMA (Colombia)

Industrial-scale production of several dosage forms, including: oil drops, creams, lotions, tablets, capsules, pellets, and chewable tablets



Product Offerings for the Global Market Place

Active Pharmaceutical Ingredients (API)

Aureus Offerings: CBD, THC, CBN, CBC, and CBG

Consumer and Retail Products

CBD derma-cosmetics: Pura Earth Offered through retail outlets in Colombia

Rx and Medical Products

Phytotherapeutic products: RHO Phyto and pharmaceutical products with a focus on dermatology, neurology, and pain





AUREUS

SANTA MARTA

**Cannabinoid Formulations,
Active Pharmaceutical Ingredients,
and Feminized Seeds**

Colombian-based Cultivation



SATIVA
NATIVA

The Micro-climate of Santa Marta and the Foothills of the Sierra Nevada Mountains: Optimal Environmental Conditions

- Proximity to the Caribbean Sea and shipping ports
- Fertile lands, clean water, and optimal humidity levels
- 12 hours of sunlight year-round



Wind
m/s

5.5



Temp
°C

28



Rainfall
mm

545



RH
%

66



1

Sun-grown using **environmentally sustainable** practices



2

Competitive **cost advantages**, including low cost labour, land, and energy



3

Cultivated under Good Agricultural and Collection Practices (“**GACP**”)



4

Avicanna’s proprietary **extraction** and **purification** processes



5

Licenses to cultivate CBD & THC dominant strains for processing and sale in the Colombian domestic market and for export to the global market

Santa Marta,
Magdalena



Extraction, Production, Purification, and Manufacturing



High Quality Pharmaceutical Grade API and Bulk Formulations

Utilizing proprietary extraction and purification processes in line with GMP standards and full quality controls meeting Health Canada, European Pharmacopeia, and USP standards

Product Offerings: CBD, THC, CBN, CBC, and CBG

- Whole plant crude oils (60-70% purity)
- Cannabinoid distillate (80-95% purity)
- Isolated and purified cannabinoid (98-99% purity)
- Cosmetic and food grade CBD/CBN



Exclusive Partnership

Global GMP Certifications


- ANVISA (Brazil)
- DIGMID (Perú)
- EU
- HEALTH CANADA
- INVIMA (Colombia)

GMP Manufacturing of

- Pharmaceutical products
- Phytotherapeutic products
- Derma-cosmetic products

Dosage Forms:

Oil drops, creams, lotions, tablets, capsules, pellets, and chewable tablets





PURA
EARTH

Consumer and Retail Derma-cosmetic Products

PRODUCT LAUNCH EXPECTATIONS*:

- Colombia
- ✓ Launched in 59 Locations
(Cromantic & BLIND)
- EU 1H20
- USA 1H20



About Pura Earth

CBD Derma-cosmetics

With completed clinical trials for derma-cosmetic formulations to support and improve the health and appearance of the skin.

At Pura Earth we believe in the power of nature to enhance the health and appearance of skin, and in the power of science to amplify these benefits. The result is a unique line of premium natural skin care products developed with CBD from organic hemp to deliver results you'll see and feel—from the inside out.



Completed Cosmetic Clinical Trials



Anti-aging Serum

Overview

- Study Design: 1 arm, n=54

End Points

- **Primary endpoint:** Evaluation (visual) in the improvement of fine lines & dark spots associated with aging
- **Secondary endpoints:** Viscoelasticity, hydrating effect, TEWL, tolerability/acceptability & satisfaction

Results

- Sustained hydration*
- Fast hydration
- Maintains a normal and healthy pH of the skin



Intensive Moisturizing Cream

Overview

- Study Design: 1 arm, n=54

End Points

- **Primary endpoint:** Hydrating effect
- **Secondary endpoints:** Sebum production, sensory evaluation (oily skin feeling), lesions evaluation (acne), tolerability/acceptability, QoL

Results

- Sustained hydration*
- Improves the perceived look of oily skin
- Improved perceived appearance of the skin
- Doesn't exacerbate (irritate) oily skin
- Hydrates oily skin



Clear Skin Gel

Overview

- Study Design: 1 arm, n=54

End Points

- **Primary endpoint:** Hydrating effect
- **Secondary endpoints:** Viscoelasticity, skin softness, erythema, TEWL, tolerability/acceptability

Results

- Sustained hydration*
- No perceived greasy after feel

*Clinically tested that applying cream twice per day results in sustained hydration.



Medical and Rx products

PRODUCT LAUNCH EXPECTATIONS*:

✓ **USA (California) 4Q19****

- Colombia 1H20
- Canada 1H20
 - UK 1H20
 - EU 1H20
- Australia 1H20

*The product launch expectations are conditional upon regulatory approvals

**RHO Phyto products were launched in California through a license agreement with the California based company LC2019 CA, Inc

Note: The product mock-up that appears on this page is not indicative of final products that may be marketed and sold

RHO Phyto - Canada: 1H20

Exclusive distribution agreement with Medical Cannabis by Shoppers™

Shoppers Drug Mart is Canada's leading drug store retailer with more than 1,300 pharmacist-owned locations from coast to coast



About Medical Cannabis by Shoppers™

Medical Cannabis by Shoppers™ provides access to high-quality cannabis through online ordering. Shoppers is leading the way by connecting patients with a variety of medical cannabis options and guiding product choice through the advisors and pharmacists on the Shoppers cannabis care team. Registered patients benefit from convenience, selection, and support from trained professionals.

RHO Phyto - CBD and CBD/THC Offerings

RHO Phyto offers advanced cannabinoid-based products, which are scientifically designed to provide precise dosing




- Medical only - Prescription through practitioners
- Pharmaceutical sales approach



Organic and sustainable source of natural cannabis, formulated into cannabinoid-based phytotherapies



USP-NF (pharmaceutical grade) ingredients, manufactured in accordance with Health Canada and EU GMP standards



RHO Phyto - Products and Bio-availability Results



Soft Gel Capsules: High Bioavailability

Designed for controlled dosage and delivery






Sublingual Spray: Rapid Onset


Sublingual formulation



Topical Cream: Local Delivery

Topical cream formulation designed for local application







**Pharmaceutical and Indication Specific Products
with a Focus on: Neurology, Pain, and Dermatology**


Pharmaceutical Pipeline





Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada, FDA (United States) and INVIMA (Colombia)


-  **Dermatology**
- Epidermolysis Bullosa
 - Eczema
 - Acne
 - Psoriasis

-  **Pain**
- Chronic pain
 - Neuropathic pain
 - Localized pain

-  **Psychiatry**
- Post-traumatic Stress Disorder (“PTSD”)
 - Anxiety and Depression
 - Sleep disorders

-  **Oncology**
- Palliative care
 - Ovarian Cancer

-  **Neurology**
- Epilepsy
 - Parkinson’s Disease
 - Multiple Sclerosis

-  **Oral Health**
- Gingivitis

All Clinical Trials	Pre-Clinical	Protocol Development	Protocol Established	Ethics Approval	Clinical Study
Cosmetic Trials					
Eczema Prone Skin					Complete
Acne Prone Skin					Complete
Skin Rejuvenation					Complete
Oral Care Mouthwash					
Real-World Evidence (RHO Phyto)					
Opioid Sparing				Pending Approval	
Pain Related to Inflammatory Bowel Disorder					
Cognition & Balance in Parkinson’s Disease					
Pharmaceutical Trials					
Epidermolysis Bullosa*					Phase II Pending
Prevalance of Neuropathic Pain in Sickle Cell Anemia					Near Completion
Neuropathic Pain in Sickle Cell Anemia*					
Eczema*					
Arthritis					

* Phase I studies not required for this product; Pending regulatory approval.

Clinical Trials



Epidermolysis Bullosa Phase II/III

Status: PreCTA meeting Completed November 2019
CTA Submission to Health Canada March 2020

Trial Title: The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients with Epidermolysis Bullosa ("EB"): A Phase II/III trial

Principal Investigator: Dr. Elena Pope, MD, MSc
Co-Investigator: Dr. Irene Lara-Corrales, MD, MSc

Trial Objectives: Phase II/III study exploring the safety, tolerability, and efficacy of topical application of CBD on acute and chronic wounds affecting patients with EB

Study Design: Phase II: Open label cohort study;
Phase III: Randomized, placebo controlled, blinded study, right vs left side extremity

Main Inclusion Criteria: Wounds that have not healed for over 4 weeks

Years of Age: 4-50

Study Duration: Phase II: 4 Weeks / Phase III: 8 Weeks

Centre: The study will be conducted in the specialized EB Clinic at SickKids Hospital, Toronto.

End Points:

Phase II: Tolerability (percentage of patients who experience any discomfort or, worsening that could be related to the medication), Safety (percentage of patients that needed to stop the medication as a result of an adverse event) and Target wounds' area (percentage change of area from baseline)

Phase III: Efficacy (blister count, pain, itch, improvement in wound healing, improvement in disease state) and safety (stopped medication, adverse effects, concentration of CBD in the blood, infection in the wound)

Neuropathic Pain in Patients with Sickle Cell

Status: Near Completion

Next steps: Protocol development for Phase IIa Intervention Study

Trial Title: Neuropathic Pain in Patients with Sickle Cell

Principal Investigator: Monika Parshad-Asnani, DM PhD
Study Director: Zachary Ramsay, MBBS

Trial Objectives: Prevalence study to determine the occurrence of neuropathic pain among Jamaicans with Sickle Cell Disease (SCD) and to conduct: Phase IIa: Interventional study with Avicanna's proprietary sublingual tablets to measure safety, tolerability and efficacy for neuropathic pain

Study Design: Prevalence study

Main Inclusion Criteria:

Years of Age: 14+

Study Duration: 6 months

Centre: The study will be conducted in the specialized Sickle Cell division at The University of The West Indies

Patients identified with Neuropathic pain will be selected for our phase II study (clinical protocol in development)

Link to Clinical Trial

<https://clinicaltrials.gov/ct2/show/NCT04015401?term=Avicanna&rank=3>

Patent Application and Intellectual Property



Application No.	Invention Title	Date of Filing	Status
US 62/887,158	Methods of cannabis cultivation	August 15, 2019	Filed, awaiting examination
US 62/896,408	Oral cannabinoid compositions and methods for treating neuropathic pain	September 5, 2019	Filed, awaiting examination
US 62/923,905	Topical cannabinoid compositions for clear skin	October 21, 2019	Filed, awaiting examination
US 16/709,489	Topical skin care composition and methods for treating eczema	December 10, 2019	Filed, awaiting examination
US 62/986,028	Topical cannabinoid compositions and methods for treating skin diseases	March 6, 2020	Filed, awaiting examination

Financial Highlights



Common Shares*: 23,187,444

- **Fully diluted: 27,360,554**
- **Free Float: 12,991,296**
- **Director Escrow: 7,176,850****
- **Officers Escrow: 540,743****
- **39 Month Escrow: 2,814,032*****

Market cap: \$21.499M (CAD) – at market close on March 30th 2020 (\$0.93 CAD)****

Last Financing (January 2020): \$2.06M | \$2.50 Per Share)

Industry Peer Analysis as of March 30th 2020

CANNABINOID PHARMACEUTICALS

GW Pharmaceuticals:

NASDAQ: GWPH | \$2.733B (USD) Market Cap

Zynerba Pharmaceuticals Inc:

NASDAQ: ZYNE | \$86.451M (USD) Market Cap

Lexaria Bioscience Corp:

LXX.CN | \$36.534M Market Cap

COLOMBIAN CULTIVATION

PharmaCielo Ltd.:

TSXV:PCLO | \$92.615M Market Cap

Khiron Life Sciences Corp:

TSXV: KHRN | \$44.637M Market Cap

Clever Leaves

(Private) | \$250M Market Cap

* Number of common shares issued and outstanding as of March 30, 2020.

** 10% to be released on July 1, 2020 and 15% to be released every six months thereafter.

*** 10% released in October 2019 and 15% to be released every six months thereafter.

**** www.bloomberg.com

Executive Management Team



Aras Azadian, M.Mgmt

Chief Executive Officer

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company.

Setu Purohit, JD

President and Chief Legal Officer

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. Setu has been involved in the cannabis industry for several years as an advocate for patients' rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Prior to co-founding Avicanna, Setu operated his own private practice since 2012.

Dave Sohi, CPA, CA, CBV

Chief Financial Officer

Dave received his Chartered Accountant designation in 2008, and following three years in audit and tax he joined the firm's business advisory practice as a manager. Dave's main focus in that group's practice was on mergers and acquisitions and valuation services. In 2010, Dave obtained his Chartered Business Valuator designation, and in 2013 joined Ernst and Young's Transaction Advisory Practice. Following a year with Ernst and Young, Dave opened his own practice where he provided clients with accounting and advisory services.

Dr. Amza Ali, MD, FRCP, MBA

Chief Medical Officer

Dr. Ali is certified in Neurology by the Federation of Royal Colleges of Physicians of the United Kingdom, and in clinical neurophysiology by the American Board of Clinical Neurophysiology. He is the President of the Epilepsy Society of the Caribbean. Additionally, he has an MBA from Rotman and an MSc in Research Methodology at the Henley Business School in the UK. Business School in the UK.

Dr. Justin Grant, PhD, MBA

EVP Scientific Affairs

Dr. Grant has over 15 years of experience in leading pharmaceutical research in sustained drug release formulations, has held academic positions at UHN and U of T and served as the research program manager of the STTARR Innovation Centre with Princess Margaret Cancer Centre UHN.

Lucas Nosiglia, MFin

Chief Agricultural Officer

Lucas is a seasoned entrepreneur and executive with experience across Europe, North America and South America. Lucas has been at the forefront of Avicanna's Latin America (LATAM) operations since the company's inception in 2016. His innovative and transformative approach in navigating the cannabis industry and his former involvement in management consulting, finance and health care have been invaluable in establishing Avicanna's cultivation projects that. Lucas graduated with an Honours degree from Faculty of Economics of University of Buenos Aires and holds a Masters degree in Finance from EADA in Barcelona Spain.

Board of Directors

Aras Azadian, M.Mgmt
Chief Executive Officer

Setu Purohit, JD
President, Director and Chief Legal Officer

Dr. Chandrakant Panchal
Chairman

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers Corp. since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics Corp. (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

David Allan White
Director

Mr. White is a director and chair of audit committees of several Toronto Stock Exchange ("TSX") and NASDAQ companies. Mr. White has held several senior financial positions with John Labatt Limited, Lawson Marden Group Inc. and Laidlaw Inc. and most recently as Chief Executive Officer of TransCare Inc., a medical transportation company and as President and Chief Executive Officer of Student Transportation of America, a TSX listed company. In addition to sitting on Avicanna's Board of Directors and chairing the Corporation's audit committee, Mr. White has also been a corporate director and business consultant for FirstCall Services, a private holding company and advisory firm, since 2012. Mr. White has been a Canadian Chartered Accountant since 1978 and holds a Master of Business Administration degree from the University of Toronto.

Benjamin Leavenworth
Director

Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America. Mr. Leavenworth is currently the Chief Strategy Officer of Afina International LLC ("Afina"), a specialist advisory and finance firm, and also serves as Honorary Consul of Chile for Pennsylvania, Delaware, and southern New Jersey. Prior to co-founding Afina in 2011, Mr. Leavenworth founded and ran the Chispa Group, an international consultancy with a focus on mining, energy, agriculture, and government projects across Latin America. He also serves as president of the board of Pata Foods, a leading organic baby food producer, and as a director on the boards of the Chilean & American Chamber of Commerce, Global Independence Center, Pan America Associations, and the Consular Corps Association of Philadelphia.

Giancarlo Davila Char
Director

Mr. Char has experience with sustainable and organic cultivation and production of industrial scale palm oil as well as other agriculture crops such as avocados and coffee beans. In 2017, Mr. Char went on to lead a new branch of his family's business which is dedicated to producing private label oils for national distribution in supermarkets across Colombia. This business unit reached USD\$30,000,000 in sales in 2018. Mr. Char holds a Bachelor of Science in Business Administration from Northeastern University.

Janet Giesselman
Director

A Corporate Director at: Ag Growth International Inc. Omnova Solutions Inc. Twin Disc, Incorporated and at McCain Foods Limited, where she serves as Chair of the Environmental Health & Safety Committee as well as on the Audit and the Compensation and Management committees. Ms. Giesselman retired as the President and General Manager of Dow Oil & Gas, a business unit of The Dow Chemical Company, and has over 30 years of U.S. and international agriculture, energy and specialty and commodity chemicals industry experience in U.S., Europe, Latin America, the Middle East and Asia. Ms. Giesselman holds a B.Sc., Biology from Pennsylvania State University and a Masters in Plant Pathology from the University of Florida.



Senior Scientific Team

SENIOR SCIENTIFIC TEAM

Dr. Frantz Le Devedec, PhD
SVP R&D

Dr. Carlos Maldonado, MD
SVP Clinical Development

Roland Alvarez
VP, Technical Operations

Samantha Watt, MSc
VP of Scientific Affairs

Pauric Bannigan
Senior Formulation Scientist

GLOBAL SCIENTIFIC ADVISORY BOARD

Dr. Humberto Reynales, Md, Phd
CAIMED

Dr. Mauricio Torres-pradilla, Md, Phd
Fundación Universitaria De Ciencias

Dr. Daniel N. Sauder
John Hopkins School of Medicine

GLOBAL BUSINESS ADVISORY BOARD

Alan Friedman
Rivonian Capital

Dr. Alexis Movrammatis
ESADE Business School

Felipe Gurrero
El Grupo Daabon

Javier Hasse
Benzinga

Major Milestones



3Q19

- ✓ IPO on the TSX senior exchange as an R&D issuer
- ✓ Canadian Cannabis Research Licence issued at MaRS Discovery District, Toronto
- ✓ First export of cannabinoids for R&D purposes from Colombia to Canada
- ✓ Commencement of clinical trials on 3 Pura Earth products by CAIMED

4Q19

- ✓ Organic (USDA) certification
- ✓ Retail and e-commerce launch of Pura Earth in Colombia
- ✓ First commercial exports of CBD API's out of Colombia
- ✓ Phase 1 cultivation capacity (410,000 sq/ft) completion at both SMGH and SN in Santa Marta

Expected Upcoming Milestones*

1H20

- ✓ Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart Inc., to distribute Avicanna's RHO Phyto and Pura Earth products across Canada
- ✓ Completion of clinical trials on 3 Pura Earth products by CAIMED
 - Commencement of phase IIa Epidermolysis Bullosa trials at the Hospital for Sick Children in Toronto
 - Retail and e-commerce launch of Pura Earth in Europe (Germany and the UK)
 - Launch medical products in Colombia under the compound pharmacy model (Magistral)
 - First commercial export of THC API's and THC products out of Colombia
 - First commercial export of RHO Phyto products

2H20

- Phase II expansion of SMGH and SN cultivation capacity in Santa Marta
- Expansion of Pura Earth products into tier 2 countries (Mexico, Australia, Japan, and South Africa)
- Expansion of Rho Phytotherapeutics products into Europe, Mexico, and Australia
- Completion of EB studies and commencement of phase IIa neuropathic pain studies at UWI
- Phytotherapeutic registration of specific RHO Phyto medical products in Colombia
- EU - GMP certification of SMGH for extraction and production of API



AVICANNA™

✉ ir@avicanna.com

☎ +1 647-243-5283